10-12 September 2018 //  Lancaster Royal Hotel, London


Michael Covington

Mr Michael Covington

Principal CMC Regulatory Policy and Strategy, Juno Therapeutics, Inc

Michael is a dedicated professional with over 25 years of Biotechnology, Cellular, and Gene Therapy experience in areas including Regulatory Affairs, Regulatory Compliance, Quality, Validation, and Manufacturing.   He is a leader with demonstrated success in supporting important commercial recombinant protein therapeutics including Epogen (epoetin alfa), Aranesp (darbepoetin alfa), Neupogen (G-CSF), and Kineret (IL-1ra).   Additional experience has been garnered in supporting innovative autologous cellular immunotherapies including Provenge (Commercial, CD54 antigen presenting cells), Nuevenge (Phase II, CD54 antigen presenting cells), and autologous genetically modified T cell immunotherapies such as CD19 CAR T cells.  Michael has worked with Monsanto, Amgen, Dendreon, and is currently working with Juno Therapeutics.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad